News
GENE
0.7650
+3.99%
0.0299
Weekly Report: what happened at GENE last week (1118-1122)?
Weekly Report · 51m ago
Weekly Report: what happened at GENE last week (1111-1115)?
Weekly Report · 11/18 10:46
Weekly Report: what happened at GENE last week (1104-1108)?
Weekly Report · 11/11 10:56
Weekly Report: what happened at GENE last week (1028-1101)?
Weekly Report · 11/04 10:54
Genetic Technologies Faces NASDAQ Compliance Challenge
TipRanks · 10/28 12:28
Weekly Report: what happened at GENE last week (1021-1025)?
Weekly Report · 10/28 10:48
Weekly Report: what happened at GENE last week (1014-1018)?
Weekly Report · 10/21 10:45
Bullish Monday For Marijuana Stocks - Body and Mind, Global Compliance Among Top Gainers
Benzinga · 10/14 20:30
Weekly Report: what happened at GENE last week (1007-1011)?
Weekly Report · 10/14 11:07
Marijuana Stock Movers For October 7, 2024
Benzinga · 10/07 20:30
Weekly Report: what happened at GENE last week (0930-1004)?
Weekly Report · 10/07 10:59
Marijuana Stock Movers For October 3, 2024
Benzinga · 10/03 20:30
Genetic Technologies Embraces Corporate Governance Standards
TipRanks · 10/01 12:28
Genetic Technologies Reinforces Governance Standards
TipRanks · 10/01 12:27
Weekly Report: what happened at GENE last week (0923-0927)?
Weekly Report · 09/30 10:53
Cannabis Stock Movers For September 25, 2024
Benzinga · 09/25 20:30
Weekly Report: what happened at GENE last week (0916-0920)?
Weekly Report · 09/23 10:52
Bullish Sentiment Across The Cannabis Space - Check Full Movers For September 19, 2024
Benzinga · 09/19 20:30
Bullish Wednesday For Marijuana Stocks - Australis Capital, Leafbuyer Techs Among Top Gainers
Benzinga · 09/18 20:30
Marijuana Stock Movers For September 16, 2024
Benzinga · 09/16 20:30
More
Webull provides a variety of real-time GENE stock news. You can receive the latest news about Genetic Technologies through multiple platforms. This information may help you make smarter investment decisions.
About GENE
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor